Jazz Pharmaceuticals (JAZZ) Acquries EUSA Pharma for $650M

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) signed a definitive agreement to acquire EUSA Pharma, a privately-held, specialty pharmaceutical company with headquarters in the United States and United Kingdom, for $650 million in cash(1) and a potential $50 million milestone payable in cash based upon its lead product, Erwinaze™ (asparaginase Erwinia chrysanthemi), achieving a specified U.S. net sales target in 2013.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Bernstein on whether Hershey (HSY) could eventually step up to buy Mondelez (MDLZ)
• Magna Holdings makes unsolicited bid for 31% of Yatra Online
• TMCR raises $165M to acquire additional Mesabi iron ore royalty